Nanjing Fangshenghe (南京方生和医药科技有限公司) develops differentiated generic pharmaceuticals and pursues commercialization of those products. The company operates a 5,000 sqm research center and has a joint venture with Jiangsu Yongda Pharmaceutical. It currently has four projects in research, two of which have passed bioequivalence clinical trials, including the heart‑failure drug Entresto that the company identifies as the first domestically. Founded in October 2015 and operational since June 2016 in Pukou District, Nanjing, the company has been recognized as a provincial and municipal high‑tech/small‑and‑medium enterprise. Following recent financing, Fangshenghe plans to expand its R&D pipeline, strengthen its R&D platform, and accelerate product commercialization. As of the latest round, the company has cumulatively raised ¥180 million.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2018